# Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas

> **NCT07448480** · — · ACTIVE_NOT_RECRUITING · sponsor: **Blokhin's Russian Cancer Research Center** · enrollment: 1000 (actual)

## Conditions studied

- Recurrent Malignant Glioma
- Glioblastoma
- Anaplastic Astrocytoma
- Pleomorphic Xanthoastrocytoma

## Interventions

- **DRUG:** Bevacizumab-Containing Regimens
- **DRUG:** Non-Bevacizumab Regimens
- **DRUG:** BRAF ± MEK Targeted Therapy

## Key facts

- **NCT ID:** NCT07448480
- **Lead sponsor:** Blokhin's Russian Cancer Research Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2027-10-01
- **Final completion:** 2027-10-01
- **Target enrollment:** 1000 (ACTUAL)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07448480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07448480, "Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07448480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*